Talecris Biotherapeutics and one of its rivals are both being reprimanded by federal regulators, according to Bloomberg News.
The RTP-based Talecris, which also has operations in Clayton, overstated the benefits of its drug Prolastin in promotional brochures, according to a letter on the Food and Drug Administration's Web site.
The FDA also found that CLS, an Australian company, marketed its drug Zemaira by indicating that it worked better than studies have shown, Bloomberg reported.
Both drugs are used to treat emphysema.
The FDA ordered the companies to stop handing out the promotional material and to revise their marketing of the drugs.